Crestor loses market share following AHA journal article

Share this article:

AstraZeneca's Crestor lost U.S. market share following the publication of a negative report in the journal of the American Heart Association, Circulation, according to figures cited by brokers this week.          
Crestor's new prescription market share fell to 6.1 percent from 6.6 percent in the week ending May  27 and to 5.8 percent in the following week, London-based Code Securities investment banking house analyst Paul Diggle told Reuters.
"If U.S. market share remains below 6 percent, management will face a dilemma deciding whether to continue the very high level of
Crestor promotional support or to ease back spending to protect financial performance," Diggle said in a investors note where he rated the stock to "underperform."                                           Circulation published a critical review on Crestor in its May 23 issue. The article said Crestor had twice as many side effects, including deaths, of rival statin drugs.

Share this article:

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.